Loading organizations...
Green Cross Holdings, a South Korean biopharmaceutical company based in Yongin, was established on October 5, 1967, by founder Dr. Young-sup Huh, with Eun Chul Huh serving as current President. It specializes in the research, development, manufacturing, and sale of biotherapeutics, including plasma-derived products, recombinant antibodies, vaccines, and diagnostic reagents. The company is recognized for developing the world's third Hepatitis B vaccine and the first Epidemic Hemorrhagic Fever vaccine in 1988. Green Cross operates 3 production plants and maintains 8 US plasma collection centers, gathering 400,000 liters annually to secure supply for its therapeutics. Its global footprint includes subsidiaries like GCBT in Montreal, targeting North American and European markets, and overseeing brands such as GC Pharma and GC Wellbeing.
Green Cross Holdings has 5 tracked investments across 4 companies. The latest tracked deal is $17.0M Series B in MiNDCAFE in February 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2022 | MiNDCAFE | $17.0M Series B | Hashed | E&Investment, Insight Equity Partners, K2 Investment, Samsung Next |
| Feb 1, 2021 | Artiva Biotherapeutics | $120.0M Series B | Venrock | 5AM Ventures, Frazier Healthcare Partners, VenBio Partners, Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Green Cross LabCell, Janus Henderson Investors, Logos Capital, RA Capital Management, RTW Investments, Surveyor Capital, Wellington Management |
| May 13, 2015 | Juventas Therapeutics | $13.5M Debt / Series B | Green Cross Holdings, Posco Technology Investment | Oxford Finance |
| Nov 20, 2013 | Argos Therapeutics | $17.5M Series E Extension | — | Aurora Funds, Forbion, Intersouth Partners, Lumira Ventures, Morningside, Pharmstandard International, TVM Capital |
| Aug 28, 2013 | Argos Therapeutics | $42.5M Series E | Alexandr Shuster | Aurora Funds, Forbion, Intersouth Partners, Lumira Ventures, Morningside, TVM Capital |
